

amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier or diluent.

15. Use of a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament A ~~method~~ for the treatment of disorders responsive to the reduction of β -amyloid peptide production in a mammal in need thereof, ~~which comprises administering to said mammal a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.~~

16. A ~~method~~-use of claim 15 wherein said disorder is selected from Alzheimer's Disease (AD), Down Syndrome, mild cognitive impairment (MCI), cerebral amyloid angiopathy (CAA), dementia with Lewy bodies (DLB), amyotrophic lateral sclerosis (ALS-D), inclusion body myositis (IBM), age-related macular degeneration, and cancer.

17. A ~~method~~-use of claim 16 wherein said disorder is selected from Alzheimer's Disease and Down Syndrome.

18. A ~~method~~-use of claim 17 wherein said disorder is Alzheimer's Disease.